株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

麻酔薬の世界市場:成長率、動向および予測(2019年~2024年)

Anesthesia Drugs Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 390890
出版日 ページ情報 英文 112 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=110.56円で換算しております。
Back to Top
麻酔薬の世界市場:成長率、動向および予測(2019年~2024年) Anesthesia Drugs Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年02月01日 ページ情報: 英文 112 Pages
概要

世界の麻酔薬市場は2018年に45億1,211万米ドルの規模に達し、2024年には53億1,466万米ドルに達し、2019年から2024年の予測期間にわたって4.20%のCAGRで成長する見込みです。同市場の成長を推進する主な要因は、手術数の増加と麻酔薬の新規承認などです。

当レポートでは、世界の麻酔薬市場を調査し、全体的な市場動向、薬の種類・投与ルート・アプリケーション・地域別の詳細動向、市場成長への影響要因の分析、競合情勢、主要企業のプロファイルなどを包括的にまとめています。

目次

第1章 イントロダクション

  • 調査の成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場のダイナミクス

  • 市場概況
  • 市場成長要因
    • 手術数の増加
    • 麻酔薬の新規承認
    • 新たに発明された医薬品のコスト削減
  • 市場阻害要因
    • 一般的な麻酔薬の副作用
    • 熟練した麻酔科医の不足
    • 規制の問題
  • ポーターのファイブフォース分析
    • 新規参入の脅威
    • 新規参入者の脅威
    • 買い手/消費者の交渉力
    • 売り手の交渉力
    • 代替製品の脅威
    • 業界内の競合の激しさ

第5章 市場セグメンテーション

  • 薬の種類別
    • 一般麻酔薬
    • 局所麻酔薬
  • 投与ルート別
    • 吸入
    • 注入
    • その他の投与ルート
  • アプリケーション別
    • 一般外科
    • 形成外科
    • 美容整形
    • 歯科手術
    • その他のアプリケーション
  • 地域
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Baxter
    • Hospira
    • Abbott Laboratories
    • AstraZeneca
    • F. Hoffmann-La Roche AG
    • B. Braun Melsungen AG
    • AbbVie Inc.
    • Boehringer Ingelheim International GmbH
    • エーザイ
    • Fresenius SE & Co. KGaA

第7章 市場機会および将来動向

目次
Product Code: 53145

Market Overview

The anesthesia drugs market was valued at USD 4,512.11 million in 2018, and is estimated to be valued at USD 5,314.66 million in 2024, while witnessing a CAGR of 4.20% over the forecast period of 2019-2024. The key factors propelling the growth of this market are the increasing number of surgeries and new approvals of anesthetic drugs.

There are wide ranges of surgeries based on the length of stay for surgeries. These include elective surgery and emergency surgery. Based on procedures, there are wide ranges of surgeries, where open surgery is most common. Others include keyhole surgery, laparoscopic surgery, microsurgery, and cosmetic surgery. In recent years, several articles have reported a significant rise in the number of day care procedures (ambulatory surgery), and diagnostic and therapeutic services. This is primarily due to the increased dependence on advances made in anesthesia, surgical, and medical technologies.

Furthermore, the rise in surgeries is attributed to the increasing risk of various accidents, sports injuries, and diseases, globally. According to the Center of Disease Control and Prevention (CDC), more than 51 million inpatient surgeries and 53 million outpatient surgeries were performed in the United States in 2017. In the European region, in England, nearly 4.7 million patients were admitted for surgeries in 2014, as per the Royal College of Surgeons. This indicates the rising number of surgeries, which ultimately results into the rising demand for the anesthesia drugs and propels the growth of the anesthesia drugs market.

Scope of the Report

Anesthesia is a drug that causes a reversible loss of sensation. There are several types of anesthetic drugs available in the market, such as general anesthesia, spinal anesthesia, IV regional anesthesia, local anesthesia, peripheral nerve block, and saddle block or caudal anesthesia.

Key Market Trends

Propofol Sub-segment is Expected to Show the Fastest Growth in the General Anesthesia Drugs Segment

The propofol sub-segment of the anesthesia drugs market is expected to experience a fast growth rate while witnessing a CAGR of 4.20% over the forecast period.

Propofol is a drug that has been used for a long time for various surgical procedures requiring anesthesia. Teva Pharmaceuticals had stopped manufacturing propofol for a particular time; however, the drug returned to the market in 2013. Hospira is another major player in the propofol sub-segment. In 2015, Pfizer acquired Hospira and created a leading global established pharmaceutical (GEP) business. Some of the companies who manufacture propofol injections are Neon Laboratories Limited, Bharat Serums and Vaccines Limited, and Fresenius Kabi. The drug is always in demand in the market for utilization in different surgeries, and is expected to witness rapid growth in the coming years.

North America Dominates the Market and is Expected to Follow the Same Trend Over the Forecast Period

North America currently dominates the anesthesia drugs market and is expected to continue its stronghold for a few more years. The US anesthesia market is the largest regional market in the world. This market is driven by factors, such as the increasing number of surgeries, rising aging population with increasing chronic conditions, and advancements in anesthesia technologies.

Competitive Landscape

The anesthesia drugs market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with rising drug approvals, mid-size to smaller companies are increasing their market presence by introducing new ingredients with fewer prices. Companies, like Baxter, Abbott Laboratories, AstraZeneca, Roche Holding AG, and Boehringer Ingelheim, hold substantial market shares in the anesthesia drugs market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Number of Surgeries
    • 4.2.2 New Approvals of Anesthetic Drugs
    • 4.2.3 Reduction in the Cost of Newly Invented Drugs
  • 4.3 Market Restraints
    • 4.3.1 Side Effects of General Anesthetics
    • 4.3.2 Lack of Skilled-Anesthetics
    • 4.3.3 Regulatory Issues
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Type
    • 5.1.1 General Anesthesia Drugs
      • 5.1.1.1 Propofol
      • 5.1.1.2 Sevoflurane
      • 5.1.1.3 Desflurane
      • 5.1.1.4 Dexmedetomidine
      • 5.1.1.5 Remifentanil
      • 5.1.1.6 Midazolam
      • 5.1.1.7 Other General Anesthesia Drugs
    • 5.1.2 Local Anesthesia Drugs
      • 5.1.2.1 Bupivacaine
      • 5.1.2.2 Ropivacaine
      • 5.1.2.3 Lidocaine
      • 5.1.2.4 Chloroprocaine
      • 5.1.2.5 Articaine
      • 5.1.2.6 Benzocaine
      • 5.1.2.7 Local Anesthesia Drugs
  • 5.2 By Route of Administration
    • 5.2.1 Inhalation
    • 5.2.2 Injection
    • 5.2.3 Other Routes of Administration
  • 5.3 By Application
    • 5.3.1 General Surgeries
    • 5.3.2 Plastic Surgery
    • 5.3.3 Cosmetic Surgeries
    • 5.3.4 Dental Surgeries
    • 5.3.5 Other Applications
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 US
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 UK
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East & Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Baxter
    • 6.1.2 Hospira
    • 6.1.3 Abbott Laboratories
    • 6.1.4 AstraZeneca
    • 6.1.5 F. Hoffmann-La Roche AG
    • 6.1.6 B. Braun Melsungen AG
    • 6.1.7 AbbVie Inc.
    • 6.1.8 Boehringer Ingelheim International GmbH
    • 6.1.9 Eisai Co. Ltd
    • 6.1.10 Fresenius SE & Co. KGaA

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top